# Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC

> **NCT04340258** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Cincinnati** · enrollment: 50 (estimated)

## Conditions studied

- HNSCC

## Interventions

- **DEVICE:** Cesium-131
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04340258
- **Lead sponsor:** University of Cincinnati
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-02-04
- **Primary completion:** 2025-06-03
- **Final completion:** 2025-09-04
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04340258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04340258, "Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04340258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*